The Shareholders Foundation announces that an investor, who purchased shares of Accelerate Diagnostics Inc (NASDAQ:AXDX), filed a lawsuit in the U.S. District Court for the District of Arizona over alleged violations of Federal Securities Laws by Accelerate Diagnostics Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) have certain options and for certain investors are short and strict deadlines running. Deadline: May 18, 2015. NASDAQ:AXDX investors should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
According to the complaint the plaintiff alleges on behalf of purchasers of Accelerate Diagnostics Inc (NASDAQ:AXDX) common shares between March 7, 2014 and February 17, 2015, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that the defendants allegedly misrepresented and/or failed to disclose to investors that Accelerate Diagnostics’ main product the ID/AST system, formally known as the BACcel system, requires a positive blood culture to diagnose pathogens in a blood sample.
On February 18, 2015, an article was published that asserted that Accelerate Diagnostics Inc falsely claimed that it had developed a technique for diagnosing pathogens in a blood sample without a need for using a blood culture, while in reality, the test required a blood culture, a fact that significantly reduced the value of the technology. Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) declined to as low as $17.29 per share on February 23, 2015.
On April 6, 2015, NASDAQ:AXDX shares closed at $22.40 per share.
Those who purchased shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego